<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03778502</url>
  </required_header>
  <id_info>
    <org_study_id>DUST</org_study_id>
    <nct_id>NCT03778502</nct_id>
  </id_info>
  <brief_title>DOAC in Unusual Site Venous Thrombosis</brief_title>
  <acronym>DUST</acronym>
  <official_title>International Registry on the Use of the Direct Oral Anticoagulants for the Treatment of Unusual Site Venous Thromboembolism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Malta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi dell'Insubria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Malta</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Unusual site venous thromboembolism (VTE) refers to thrombosis occurring in venous districts
      outside the veins of the lower extremities and the pulmonary arteries, and includes
      splanchnic vein thrombosis (SVT), cerebral vein thrombosis (CVT), retinal vein thrombosis,
      ovarian vein thrombosis, and renal vein thrombosis. The use of the novel direct oral
      anticoagulants (DOAC), thrombin or factor Xa-inhibitors (such as dabigatran, apixaban,
      edoxaban, rivaroxaban), in patients with unusual VTE in clinical practice is increasing.
      Through an international multicentre prospective registry, the investigators aim to evaluate
      the rationale for the use of the DOAC for the treatment of unusual site VTE and to assess the
      safety and effectiveness of this approach in real life clinical practice.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>12 Months</target_duration>
  <primary_outcome>
    <measure>Rationale for the use of the direct oral anticoagulants</measure>
    <time_frame>Baseline</time_frame>
    <description>Possible reasons for choosing one of the direct oral anticoagulant (multiple choice question)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of major bleeding events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of vascular events</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Splanchnic Vein Thrombosis</condition>
  <condition>Cerebral Vein Thrombosis</condition>
  <condition>Ovarian Vein Thrombosis</condition>
  <condition>Renal Vein Thrombosis</condition>
  <condition>Retinal Vein Thrombosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Direct Oral Anticoagulants</intervention_name>
    <description>Consecutive adult patients with objectively diagnosed unusual site venous thrombosis and treated with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban) will be eligible for this observational prospective registry</description>
    <other_name>Apixaban</other_name>
    <other_name>Dabigatran</other_name>
    <other_name>Edoxaban</other_name>
    <other_name>Rivaroxaban</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive patients who fulfill the inclusion/exclusion criteria at the participating
        thrombosis centers will be eligible
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Objective diagnosis of venous thrombosis not involving the upper limbs, lower limbs
             and pulmonary arteries

          -  Treatment with one of the DOAC (e.g. apixaban, dabigatran, edoxaban, rivaroxaban)

        Exclusion Criteria:

        • Enrolment in interventional studies evaluating the DOAC for the treatment of unusual site
        VTE
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicoletta Riva, MD</last_name>
    <phone>+356 25452518</phone>
    <email>nicoletta.riva@um.edu.mt</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Insubria</name>
      <address>
        <city>Varese</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>December 11, 2018</study_first_submitted>
  <study_first_submitted_qc>December 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2018</study_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Malta</investigator_affiliation>
    <investigator_full_name>Nicoletta Riva</investigator_full_name>
    <investigator_title>Visiting Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Edoxaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Anticoagulants</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

